|
Number of patients
|
220
|
32
|
137
|
51
|
|
Age (yrs)
|
42.9 ± 11.9
|
45.8 ± 10.1
|
41.9 ± 11.6
|
43.7 ± 13.3
|
|
Gender (male) (n, %)
|
152 (69)
|
20 (63)
|
96 (70)
|
36 (71)
|
|
Duration of symptoms (yrs)
|
15 (1 to 53)
|
21 (2 to 49)
|
15 (1 to 47)
|
11 (1 to 53)
|
|
Time since diagnosis (yrs)
|
7 (0 to 45)
|
16 (0 to 35)*
|
7 (0 to 44)
|
6 (0 to 45)
|
|
HLA-B27+ (n, %)
|
174 (81)
|
24 (75)
|
108 (82)
|
42 (82)
|
|
History of IBD (n, %)
|
20 (9)
|
8 (26)†
|
7 (5)
|
4 (8)
|
|
History of uveitis (n, %)
|
64 (29)
|
13 (40)
|
44 (32)
|
7 (14)‡
|
|
History of psoriasis (n, %)
|
13 (6)
|
3 (9)
|
8 (6)
|
13 (6)
|
|
Peripheral arthritis (n, %)
|
37 (17)
|
5 (16)
|
27 (20)
|
5 (10)
|
|
Current NSAID use (n, %)
|
158 (72)
|
24 (75)
|
102 (75)
|
32 (63)
|
|
Current DMARD use (n, %)
|
45 (21)
|
10 (31)
|
28 (20)
|
7 (14)
|
|
BASDAI (range 0 to 10)
|
6.1 ± 1.7
|
6.1 ± 1.4
|
6.2 ± 1.7
|
5.9 ± 1.7
|
|
ASDAS
|
3.8 ± 0.8
|
3.8 ± 0.6
|
3.8 ± 0.8
|
3.7 ± 0.9
|
|
Physician's GDA (range 0-10)
|
5 (0 to 9)
|
5 (0 to 8)
|
5 (0 to 9)
|
3 (0 to 9)‡
|
|
Patient's GDA (range 0 to 10)
|
7 (1 to 10)
|
6 (1 to 9)
|
7 (1 to 10)
|
6 (1 to 10)
|
|
ESR (mm/h)
|
21 (2 to 101)
|
24 (2 to 90)
|
20 (2 to 101)
|
23 (2 to 74)
|
|
CRP (mg/l)
|
13 (2 to 99)
|
15 (2 to 74)
|
12 (2 to 99)
|
14 (2 to 92)
|
|
BASFI (range 0 to 10)
|
6.1 (0.3 to 9.7)
|
6.3 (1.9 to 9.6)
|
5.9 (0.3 to 9.7)
|
6.3 (0.4 to 9.5)
|
|
Chest expansion (cm)
|
3.0 (0.5 to 43.0)
|
2.5 (0.5 to 7.0)
|
3.0 (0.5 to 22.0)
|
3.5 (0.0 to 43.0)§
|
|
Modified Schober test (cm)
|
2.9 (0.0 to 7.0)
|
2.4 (0.5 to 6.0)
|
2.8 (0.1 to 7.0)
|
3.2 (0.0 to 5.5)
|
|
Occiput to wall distance (cm)
|
4.9 (0.0 to 34.5)
|
9.0 (0.0 to 26.0)^
|
4.5 (0.0 to 34.5)
|
3.5 (0.0 to 30.0)
|
|
Lateral lumbar flexion L (cm)
|
8.0 (0.0 to 30.0)
|
7.0 (2.0 to 15.0)
|
9.0 (0.0 to 30.0)
|
8.0 (1.0 to 20.5)
|
|
Lateral lumbar flexion R (cm)
|
8.0 (0.0 to 29.0)
|
8.0 (0.5 to 17.0)
|
8.0 (0.0 to 29.0)
|
7.5 (1.0 to 20.0)
|
